These 3 shares had a terrible 2017

While 2017 has been a great year for many ASX companies, others have not done so well.

Here’s a look at 3 shares that haven’t performed so well over the past 12 months.

iSentia Group Ltd (ASX: ISD)

The iSentia Group Ltd share price has by dropped more than 50 per cent in the past year with shares in the company now trading at around $1.34.

The media monitoring company, with a market cap of about $268 million, reported revenue of $155.1 million for financial year (FY) 2017, down 1 per cent on the previous year.

The iSentia Group also reported EBITDA of $41.5 million for FY 2017, down 19 per cent on the previous year.

And, with the company forecasting EBITDA in the range of $32 million to $36 million for FY 2018, it doesn’t look like things are getting better in the near future for iSentia.

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma Group Ltd share price has shed more than 50 per cent this year.

But Mayne expects things to turn around in the next couple of years with 6 products anticipated for approval in FY 2018 and 8 potential product launches in 2019.

Mayne shares are now trading at about 63 cents but UBS analysts have tipped the pharmaceutical company’s share price to push past $1 in the next 12 months.

Thorn Group Ltd (ASX: TGA)

It hasn’t been a great year for Thorn Group Ltd shareholders who have seen their stock in the company drop by nearly 60 per cent.

Thorn, with a market cap down to $120 million, has seen its share price sink from above $3 in early 2015 to its current price of 75 cents.

The financial services company reported a loss of $9.7 million for the six month period ended 30 September, down from a profit of $15 million announced for the prior corresponding period.

If you’re interested in checking out some shares that look at bit more promising than those mentioned above, you may want to have a read of this…

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor Steve Holland has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.